Biktarvy and Cephalexin: No Clinically Significant Interaction
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) can be safely co-administered with cephalexin without dose adjustment or concern for clinically significant drug-drug interactions.
Pharmacologic Basis for Safety
Cephalexin is a first-generation cephalosporin antibiotic that does not interact with the metabolic or transport pathways relevant to Biktarvy's components 1:
- Bictegravir is metabolized equally by CYP3A4 and UGT1A1, and is a substrate of P-glycoprotein (P-gp) 2, 3
- Emtricitabine and tenofovir alafenamide are primarily renally eliminated and do not undergo significant hepatic metabolism 1
- Cephalexin is not an inducer or inhibitor of CYP3A4, UGT1A1, or P-gp, and does not affect renal tubular secretion of antiretrovirals
FDA-Approved Drug Interaction Profile
The FDA label for Biktarvy explicitly lists drugs that require dosage adjustments or are contraindicated 1. Cephalexin is not mentioned among these interactions, and the label specifically notes that "no clinically significant drug interactions have been observed" with numerous commonly prescribed medications 1.
Drugs That DO Interact with Biktarvy (for contrast):
- Contraindicated: Rifampin, dofetilide 1
- Not recommended: St. John's wort, rifabutin, rifapentine, carbamazepine, phenytoin, phenobarbital 1
- Requires separation/monitoring: Polyvalent cation-containing antacids (aluminum, magnesium, calcium, iron) 1
Clinical Practice Considerations
Biktarvy maintains high efficacy and safety across diverse clinical scenarios 4, 5, 6:
- 88-90% virologic suppression rates at 96 weeks in treatment-naïve patients 4
- No treatment-emergent resistance observed in clinical trials 4, 7, 8
- Well-tolerated with low discontinuation rates (5% due to adverse events over 24 months) 9
When prescribing antibiotics to patients on Biktarvy, the primary concern should be interactions with drugs that:
- Strongly induce CYP3A4 and/or UGT1A1 (e.g., rifamycins) 1, 2
- Contain polyvalent cations that chelate bictegravir (requiring dose separation) 1
Practical Recommendation
Prescribe cephalexin at standard doses without any timing restrictions relative to Biktarvy administration 1. No additional monitoring beyond routine HIV viral load and CD4 count surveillance is necessary 10. The integrase strand transfer inhibitor-based regimen in Biktarvy has minimal drug-drug interaction potential compared to older protease inhibitor or pharmacologically-boosted regimens 10.